Home > Healthcare > Pharmaceuticals > Finished Drug Form > Pancreatic Cancer Treatment Market

Pancreatic Cancer Treatment Market Share

Report ID: GMI9748
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Pancreatic Cancer Treatment Market Share

The competitive landscape of the market is characterized by a mix of established pharmaceutical companies, biotechnology firms, and research institutions striving to develop effective therapies for this challenging disease. Key players such as Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, and Pfizer Inc. are actively engaged in the development of novel treatment options. These companies often collaborate with academic institutions and research organizations to advance their pipelines.

Pancreatic Cancer Treatment Market Companies

Prominent players operating in the Pancreatic Cancer Treatment industry include:

AstraZeneca
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
Genentech (F. Hoffmann-La Roche Ltd.)
GlaxoSmithKline plc
Merck & Co., Inc.
Mylan N.V.
Novartis AG
PharmaCyte Biotech, Inc.
Pfizer, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for pancreatic cancer treatment was USD 3 billion in 2023 and is projected to expand at 13.2% CAGR from 2024 to 2032, due to the increasing prevalence of pancreatic cancer across the globe.

The exocrine cancer type segment in the pancreatic cancer treatment industry accounted for USD 2.6 billion in 2023, due to the advancements in treatment options, such as surgery, chemotherapy, and targeted therapy.

The targeted therapy treatment type segment in the pancreatic cancer treatment industry accounted for 38.2% share in 2023 and is projected to grow at significant rate from 2024 to 2032, due to its precision and effectiveness in combating this challenging disease.

North America market recorded USD 1.2 billion in 2023, due to the presence of advanced healthcare infrastructure, high adoption of novel therapeutics, and a strong focus on R&D.